These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9160648)

  • 1. Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.
    Kraus RP
    Depression; 1996; 4(2):92-4. PubMed ID: 9160648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal hypomania associated with paroxetine.
    Landry P; Roy L
    J Clin Psychopharmacol; 1997 Feb; 17(1):60-1. PubMed ID: 9004064
    [No Abstract]   [Full Text] [Related]  

  • 3. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy.
    Bakish D; Hooper CL; Thornton MD; Wiens A; Miller CA; Thibaudeau CA
    Int Clin Psychopharmacol; 1997 Mar; 12(2):91-7. PubMed ID: 9219044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing rapid metabolizers of antidepressants.
    Kraus RP; Diaz P; McEachran A
    Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Unipolar depression suddenly switches to hypomania in a patient who has just started taking venlafaxine].
    Krol DG; Nolen WA
    Tijdschr Psychiatr; 2006; 48(5):405-8. PubMed ID: 16956033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
    Abraham JT; Brown R; Meltzer HY
    Biol Psychiatry; 1997 Jul; 42(2):144-6. PubMed ID: 9209732
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bradycardia after beginning therapy with metoprolol and paroxetine].
    König F; Häfele M; Hauger B; Löble M; Wössner S; Wolfersdorf M
    Psychiatr Prax; 1996 Sep; 23(5):244-5. PubMed ID: 8992519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency.
    Tome MB; Isaac MT; Harte R; Holland C
    Int Clin Psychopharmacol; 1997 Mar; 12(2):81-9. PubMed ID: 9219043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjects.
    Brunswick DJ; Goodman DB; O'Reardon JP; Chopra M; Amsterdam JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):477-80. PubMed ID: 15093954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate].
    Vergouwen AC; Bakker A
    Ned Tijdschr Geneeskd; 2002 Apr; 146(17):811-2. PubMed ID: 12014241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of extrapyramidal symptoms with paroxetine.
    Arya DK; McKenzie J; Worrall N
    Aust N Z J Psychiatry; 1995 Sep; 29(3):521-2. PubMed ID: 8573063
    [No Abstract]   [Full Text] [Related]  

  • 15. Paroxetine in depressed adolescents with intellectual disability: an open label study.
    Masi G; Marcheschi M; Pfanner P
    J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():268-72. PubMed ID: 9219077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal after discontinuation of paroxetine.
    Arya DK
    Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183
    [No Abstract]   [Full Text] [Related]  

  • 18. Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure.
    Chuang YF; Chiu YL; Hwang TJ; Chu TS
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):642-3. PubMed ID: 16958954
    [No Abstract]   [Full Text] [Related]  

  • 19. Toxic epidermal necrolysis after paroxetine treatment.
    Ahmed R; Eagleton C
    N Z Med J; 2008 May; 121(1274):86-9. PubMed ID: 18535650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.